http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-0147732-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5128cfc84a0fb189fceb3cd240c44493 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-24 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 |
filingDate | 1993-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 1998-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4749813b64a8bf9aeba858785ae95233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60b3e71383ede56b5b87a638cf708e90 |
publicationDate | 1998-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-0147732-B1 |
titleOfInvention | Azepine Derivatives, Methods for Making and Uses thereof |
abstract | Azepine derivative represented by the general formula (1) or a nontoxic salt thereof, preparation method thereof, and a therapeutic agent for a disease involving a receptor, characterized by containing them as an active ingredient:n n n n n n n n [Where R is an expressionn n n n n n n n (Wherein R 1 represents a hydrogen atom, lower alkyl, lower alkoxy, hydroxy, a halogen atom or a phenyl group which may have a substituent, n is 0 or 1) 5-8 cycloalkyl, norbornyl, bicyclo [3.3.1] nonyl, naphthyl, 1,3-benzodioxolyl, pyridyl or thienyl; m is an integer from 0 to 4; C * is an asymmetric carbon atom.n n n The compound (1) and its non-toxic salts can be used to treat diseases involving receptors-such as schizophrenia-because they have high affinity for the receptor but little for other receptors. |
priorityDate | 1992-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 393.